Presentation is loading. Please wait.

Presentation is loading. Please wait.

PCC dose per manufacturer’s instructions.

Published byCarol O’Brien’ Modified over 5 years ago

Similar presentations

Presentation on theme: "PCC dose per manufacturer’s instructions."— Presentation transcript:

1 PCC dose per manufacturer’s instructions.
PCC dose per manufacturer’s instructions. For Cofact (Sanquin), the variable dose is determined using bodyweight, baseline INR and a choice in a preferred target INR of ≤2.1 (A) or ≤1.5 (B). For Beriplex (CSL Behring), the manufacturer’s instructions only provide a dosing algorithm to reach a target INR≤1.3 (C). For both Cofact and Beriplex, 10 mL corresponds to 250 IU fIX. INR, international normalised ratio; IU fIX, international units of factor IX; PCC, prothrombin complex concentrate. Rahat A Abdoellakhan et al. BMJ Open 2018;8:e020764 ©2018 by British Medical Journal Publishing Group

Download ppt "PCC dose per manufacturer’s instructions."

Similar presentations

Number of local authorities (LAs) commissioning each service directly or indirectly (n=148) (*Flu vaccination data excludes the service commissioned across.

Number of local authorities (LAs) commissioning each service directly or indirectly (n=148) (*Flu vaccination data excludes the service commissioned across.
Mean expense per year on courses and conferences that trainees have not been reimbursed. Mean expense per year on courses and conferences that trainees.

Mean expense per year on courses and conferences that trainees have not been reimbursed. Mean expense per year on courses and conferences that trainees.
Daily contribution (%) of sodium and potassium from major food groups among participants aged 8–12 years (n=517), which includes major food groups provided.

Daily contribution (%) of sodium and potassium from major food groups among participants aged 8–12 years (n=517), which includes major food groups provided.
Defining study follow-up periods—index date (entry into cohort) and breaks in MSP registration. †End of follow-up due to earliest of: active TB diagnosis,

Defining study follow-up periods—index date (entry into cohort) and breaks in MSP registration. †End of follow-up due to earliest of: active TB diagnosis,
Incidence trends for each human papillomavirus-related cancer-type among women in Norway 1953–2015. Incidence trends for each human papillomavirus-related.

Incidence trends for each human papillomavirus-related cancer-type among women in Norway 1953–2015. Incidence trends for each human papillomavirus-related.
Toxicity spectra and rankings in the subgroup analysis based on each specific grade 1-5 adverse event and cancer type. Toxicity spectra and rankings in.

Toxicity spectra and rankings in the subgroup analysis based on each specific grade 1-5 adverse event and cancer type. Toxicity spectra and rankings in.
Scatter graph showing total work time equivalent of all specialist palliative care practitioners commissioned by the Clinical Commissioning Group (CCG)

Scatter graph showing total work time equivalent of all specialist palliative care practitioners commissioned by the Clinical Commissioning Group (CCG)
(A) Indirectly age-sex-deprivation-ethnicity standardised procedure ratios for combined eye injection procedures (OPCS-4: C794 and C893) by CCG in England,

(A) Indirectly age-sex-deprivation-ethnicity standardised procedure ratios for combined eye injection procedures (OPCS-4: C794 and C893) by CCG in England,
DSM-IV delirium prevalence, including the estimated delirium prevalence in the 31 patients that did not undergo delirium assessment following initial screening.

DSM-IV delirium prevalence, including the estimated delirium prevalence in the 31 patients that did not undergo delirium assessment following initial screening.
Scatter graph showing the total number of specialist palliative care beds commissioned compared with the estimated number of people with palliative care.

Scatter graph showing the total number of specialist palliative care beds commissioned compared with the estimated number of people with palliative care.
Estimated probability of successful quitting (quit attempt of longer than 1 year) by quit attempt number in the Ontario Tobacco Survey. Estimated probability.

Estimated probability of successful quitting (quit attempt of longer than 1 year) by quit attempt number in the Ontario Tobacco Survey. Estimated probability.
Trending patterns of life expectancy by sex, SES quintile and remoteness, NSW, 2001–2012. Trending patterns of life expectancy by sex, SES quintile and.

Trending patterns of life expectancy by sex, SES quintile and remoteness, NSW, 2001–2012. Trending patterns of life expectancy by sex, SES quintile and.
Differences in life expectancy by SES, sex and remoteness, NSW, 2001 and 2012. Differences in life expectancy by SES, sex and remoteness, NSW, 2001 and.

Differences in life expectancy by SES, sex and remoteness, NSW, 2001 and Differences in life expectancy by SES, sex and remoteness, NSW, 2001 and.
Estimated changes in body mass index (difference in BMI) after October 2010 among nursery schoolchildren born between 2 April 2006 and 1 April 2007 in.

Estimated changes in body mass index (difference in BMI) after October 2010 among nursery schoolchildren born between 2 April 2006 and 1 April 2007 in.
A schematic representation of the possible pairwise comparisons of adherence and persistence between different medication classes. A schematic representation.

A schematic representation of the possible pairwise comparisons of adherence and persistence between different medication classes. A schematic representation.
Modelled mean (SEM) observed forced vital capacity (FVC) volume change from baseline (mL) over time by dose intensity (>90%, ≤90%), based on actual dose.

Modelled mean (SEM) observed forced vital capacity (FVC) volume change from baseline (mL) over time by dose intensity (>90%, ≤90%), based on actual dose.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
Transdomain Model of Health.

Transdomain Model of Health.
Funnel plot of the 17 trials comparing haloperidol and placebo in schizophrenia (outcome: response rate). Funnel plot of the 17 trials comparing haloperidol.

Funnel plot of the 17 trials comparing haloperidol and placebo in schizophrenia (outcome: response rate). Funnel plot of the 17 trials comparing haloperidol.
A. Kisilevsky, A.W. Gelb, M. Bustillo, A.M. Flexman 

A. Kisilevsky, A.W. Gelb, M. Bustillo, A.M. Flexman 

Similar presentations

Ads by Google